Literature DB >> 35707439

Bias induced by adaptive dose-finding designs.

Nancy Flournoy1, Assaf P Oron2.   

Abstract

There is a long literature on bias in maximum likelihood estimators. Here we demonstrate that adaptive dose-finding procedures (such as Continual Reassessment Methods, Up-and-Down and Interval Designs) themselves induce bias. In particular, with Bernoulli responses and dose assignments that depend on prior responses, we provide an explicit formula for the bias of observed response rates. We illustrate the patterns of bias for designs that aim to concentrate dose allocations around a target dose, which represents a specific quantile of a cumulative response-threshold distribution. For such designs, bias tends to be positive above the target dose and negative below it. To our knowledge, this property of dose-finding designs has not previously been recognized by design developers. We discuss the implications of this bias and suggest a simple shrinkage mitigation formula that improves estimation at doses away from the target.
© 2019 Informa UK Limited, trading as Taylor & Francis Group.

Entities:  

Keywords:  Bernoulli regression analysis; continual reassessment method; inference following stochastic processes; interval designs; phase I clinical trials; up-and-down procedures

Year:  2019        PMID: 35707439      PMCID: PMC9041908          DOI: 10.1080/02664763.2019.1649375

Source DB:  PubMed          Journal:  J Appl Stat        ISSN: 0266-4763            Impact factor:   1.416


  12 in total

1.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

2.  Dose-finding designs: the role of convergence properties.

Authors:  Assaf P Oron; David Azriel; Peter D Hoff
Journal:  Int J Biostat       Date:  2011-10-27       Impact factor: 0.968

3.  An integrated dose-finding tool for phase I trials in oncology.

Authors:  Shengjie Yang; Sue-Jane Wang; Yuan Ji
Journal:  Contemp Clin Trials       Date:  2015-09-28       Impact factor: 2.226

4.  Estimation in flexible two stage designs.

Authors:  Werner Brannath; Franz König; Peter Bauer
Journal:  Stat Med       Date:  2006-10-15       Impact factor: 2.373

5.  Dose-finding in phase I clinical trials based on toxicity probability intervals.

Authors:  Yuan Ji; Yisheng Li; B Nebiyou Bekele
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

6.  The k-in-a-row up-and-down design, revisited.

Authors:  Assaf P Oron; Peter D Hoff
Journal:  Stat Med       Date:  2009-06-15       Impact factor: 2.373

7.  The maximum effective needle-to-nerve distance for ultrasound-guided interscalene block: an exploratory study.

Authors:  Eric Albrecht; Kyle R Kirkham; Patrick Taffé; Ryan V W Endersby; Vincent W S Chan; Cyrus Tse; Richard Brull
Journal:  Reg Anesth Pain Med       Date:  2014 Jan-Feb       Impact factor: 6.288

8.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

9.  A modified toxicity probability interval method for dose-finding trials.

Authors:  Yuan Ji; Ping Liu; Yisheng Li; B Nebiyou Bekele
Journal:  Clin Trials       Date:  2010-10-08       Impact factor: 2.486

10.  Precision of maximum likelihood estimation in adaptive designs.

Authors:  Alexandra Christine Graf; Georg Gutjahr; Werner Brannath
Journal:  Stat Med       Date:  2015-10-12       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.